Peptide nanoassemblies have garnered remarkable importance
in the
development of novel nanoscale biomaterials for drug delivery into
tumor cells. Taking advantage of receptor mediated recognition of
two known peptides, angiopep-2 (TFFYGGSRGKRNNFKTEEY) and A-COOP-K
(ACGLSGLC10 VAK) that bind to the over-expressed receptors low density
lipoprotein (LRP-1) and fatty acid binding protein (FABP3) respectively,
we have developed new peptide conjugates by combining the anti-inflammatory,
antitumor compound azelaic acid with angiopep-2, which efficiently
self-assembled into nanofibers. Those nanofibers were then functionalized
with the A-COOP-K sequence and formed supramolecular hierarchical
structures that were found to entrap the chemotherapeutic drug doxorubicin
efficaciously. Furthermore, the nanoassemblies were found to release
the drug in a dose-dependent manner and showed a stepwise increase
over a period of 2 weeks under acidic conditions. Two cell lines (U-87-MG
and U-138-MG) were utilized as models for glioblastoma cells grown
in the presence of serum and under serum-free conditions to mimic
the growth conditions of natural tumors. The drug entrapped assemblies
were found to inhibit the cell proliferation of both U-87 and U-138MG
glioblastoma cells. Three dimensional spheroids of different sizes
were grown to mimic the tumors and evaluate the efficacy of drug release
and internalization. Our results indicated that the nanoassemblies
were found to have higher internalization of DOX and were well-spread
throughout the spheroids grown, particularly under serum-free conditions.
The nanoassemblies also displayed blood–brain barrier penetration
when tested with a multicellular in vitro model. Such self-assembled
nanostructures with targeting ability may provide a suitable platform
for the development of new peptide-based biomaterials that can provide
more insights about the mechanistic approach for drug delivery for
not only 2D cell cultures but also 3D tumoroids that mimic the tumor
microenvironments.